In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals In Depth: September 2017

Executive Summary

Halozyme will use its Enhanze technology to improve the delivery of BMS's immuno-oncology drugs in a new $1.9 billion deal; for $725 million up front and $375 million in earn-outs, Teleflex expanded its urology device portfolio with the NeoTract buy. Device financing surged due to CooperSurgical's $1.1 billion bridge loan, which is helping to support the acquisition of Teva's Paragard IUD.

You may also be interested in...

Deals In Depth: November 2019

Allergan signed an $800m deal to investigate Exicure's Spherical Nucleic Acid (SNA) gene regulation and immune modulation technology for the treatment of hair loss. Novartis invested in cardiology through the $9.7bn acquisition of The Medicines Co. Biopharma financing greatly increased due to the $30bn notes offering done by AbbVie to fund part of the Allergan deal.

Device/Diagnostics Quarterly Dealmaking Statistics, Q3 2019

Device financing increased substantially in Q3, thanks to debt raises led by Insulet. Acquisition dollar volume dropped, though, but Siemens' buy of Corindus for $1.1bn was a stand-out. Diagnostics/research tools financing dropped by 28% from Q2, while acquisition value greatly increased due to Exact Sciences' $2.8bn purchase of Genomic Health.

Deals In Depth: October 2019

BeiGene gained rights to three Amgen drugs in China in a deal worth $1.25bn, while Amgen took a $2.7bn stake in BeiGene. Nestle Skin Health was spun out as Galderma and sold to private equity for $10bn. Biopharma financing maintained the levels seen in previous months, but device funding was down.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts